Description: (Oncologist, University teacher)
Tak Wah Mak is a renowned Canadian medical researcher recognized for his groundbreaking discoveries in genetics, oncology, and biochemistry. In 1983, he made a significant breakthrough by identifying the T-cell receptor, which has since had a profound impact on the field of immunology. Mak's research also led to the unveiling of the role of the immune checkpoint protein CTLA-4 in 1995, transforming cancer treatment through immunotherapy. His contributions to the genetics of immunology have been instrumental in advancing our understanding of cancer and immune responses. Additionally, Mak played a key role in the establishment of Agios Pharmaceuticals, a company that developed IDHIFA®, the first FDA-approved cancer metabolism-targeting drug for acute myeloid leukemia. With his expertise spanning biochemistry, immunology, and cancer genetics, Mak continues to be a leading figure in the field of medical research.